FDA Office of Drug Evaluation III Approves Salix's Request that the...

Post-marketing Observations Cohort Study Required to Assess Relative Incidence of MACE in Patients using RELISTOR Subcutaneous Injection Compared to Patients Using Other Comparator Treatments for Opioid-induced Constipation RALEIGH, N.C. & TARRYTOWN, N.Y.-- -- Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals today announced that the Food ... (more)

http://ift.tt/1kodc9Z